Skip to main content

Mitigation of ADA Assay Drug Interference- Biotin-Drug Extraction and Acid Dissociation (BEAD) Method

 The circulating drug binds to the anti-drug antibodies (ADA) in the samples and interferes with the detection of ADA. The circulating drug severely reduces the sensitivity of the assay and increases the false-negative rate during clinical bioanalysis. 

Drugs can interfere with ADA detection by two mechanisms; 
a) Circulating drugs form immune complexes with ADA
b) Circulating drugs compete with the detection reagents in the assay 

Biotin-Drug Extraction and Acid Dissociation (BEAD) procedure:

BEAD method has shown to effectively remove the circulating drugs from the serum samples and reduce the drug interference in the assay. The BEAD method utilizes acetic acid to dissociate the drug-ADA complex. The sample is rapidly neutralized in the Tris-HCl containing an excess of biotinylated drug and allow binding to ADA to biotinylated drugs. 
The streptavidin-coated magnetic Bead is used to capture the biotinylated drug-ADA complex and remove any free circulating drugs. The second acid dissociation step is used to elute the ADA bound to biotinylated drugs. 
This procedure is widely used in ADA assays to reduce drug interference and improve assay sensitivity. 

Figure 1: Biotin-Drug Extraction and Acid Dissociation Method Reduced Interfering Drugs 



 1.0 Stepwise Protocol for optimization of BEAD method

a) Optimize the strength of acetic acid and neutralizing reagents: 
The first step for optimizing the BEAD method is to find the optimal strength acetic acid sufficient to dissociate the drug: ADA complex. The strength and the ratio of the acetic acid depend on the affinity of ADA: drug complex. The optimal proportion of samples to acetic acid ranges from 1:5 to 1:10 ratio. 

-Use 100-600 mM acetic acid for disruption of the drug: ADA complexes.

-Use multiple surrogate positive control antibodies with different binding affinities to optimize the strength of the acetic acid required to disrupt the ADA: drug complexes.

- Titrate the 1 mM Tris HCL to determine the volume sufficient to neutralize the acid and bring the pH of the solution to approximately 7.4. 

b) Optimize Biotinylated Drug Concentration: 
The biotinylated drug is used to capture and saturate the unbound form of ADA resulted from acid dissociation. Acid dissociation and rapid neutralization with biotinylated drugs(in Tris HCl) enable the efficient capture of ADA to biotinylated drugs and prevent the re-association of ADA with the circulating drugs. 

- The optimal concentration of the biotinylated drug depends on the concentration of circulating drugs present in clinical samples (Cmax-maximal drug concentration observed in the clinical sample) and target drug tolerance.
 
- Test various concentrations of biotinylated drugs (approximately 10-100 times higher than Cmax) prepared in neutralizing buffer (1 M Tris HCl) to find the optimal concentration that yields higher ADA recovery & reduce drug interference. 
Note: higher concentration of biotinylated drugs requires a larger volume of magnetic beads.

c) Streptavidin-coated Magnetic Beads: 
The streptavidin-coated magnetic beads are used to selective binding the biotin: drug-ADA complex from a mixture of biotin-drugs-ADA and free drugs present in the sample. The concentration/volume of magnetic beads depends on the binding capacity of the bead, the concentration of biotinylated drugs used in the assay, etc. 
-GE healthcare- Sera-Mag Bead with higher binding capacity and low sedimentation rate (microparticles) are most widely used for these types of extraction

-Test 25 to100 microliter of magnetic beads to determine the minimum amount of beads required to capture the majority of the biotin-drug-ADA complex.

d) Bead Washing and removal of the free drug: 
Use plate washer with the magnet base for washing beads and remove any free circulating drugs. The washing step is crucial and requires precaution to prevent the aspiration of any magnetic beads.

e) Elution of ADA: 
In this step, the ADA is eluted from the biotin-drug bound to the magnetic beads. 
-Use 100-600 mM acetic acid to dissociate the ADA from biotinylated drug bound to magnetic beads.

-Test different strengths and volumes of acetic acid to completely elute the ADA. Using higher volume can substantially dilute the ADA.  

- Use  96-well magnetic plate to sediment the magnetic beads and aspirate the ADA solution 

-Neutralize with 1 M Tris HCl and assay diluent and the samples are ready for running in ADA assays. 

2.0 Critical Assessment Parameters 

a) Assess ADA Recovery- >80% recovery of ADA are expected:

-Use a known (low and high) concentration of surrogate positive control  prepared buffers to determine the percent recovery and efficiency of the BEAD method

The simplest approach to determine the percent recovery from the assay signals is 
% Recovery = 
{Assay signal(without BEAD treatment)-Assay Signal (BEAD treatment)}/ {Assay signal(without BEAD treatment)

b) Assess the efficiency of drug removal: >80% drug removal efficiency are expected:

-Use a known (low and high) concentration of surrogate positive control spiked with increasing concentration of drugs (samples prepared buffers)

-Determine % Recovery of surrogate positive at each concentration of drug

-Determine the residual drug concentration in the final eluate

c) Validate the %recovery and drug removal efficiency in the sample matrix

d) Use clinical sample pool to confirm the drug interference in clinical samples 

References
Jiang et al. 2014
Xu et al. 2015,
Niu H et al. 2017


Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r
Read more

Cellular & Gene Therapy Guidances (Food and Drug Administration)

  Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial; Draft Guidance for Industry 11/2022 Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry 10/2022 Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Draft Guidance for Industry 3/2022 Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry 3/2022 Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Guidance for Industry 9/2021 Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency; Guidance for Industry 1/2021 Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry 1/2020 Long Term Follow-up After Administration of Human Gene Therapy Products; Guidance for Industry 1/2020 Testing of Retroviral Vecto
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quantification of si
Read more

Engineering AAV vectors for enhanced safety profiles

 Engineering AAV vectors for enhanced safety profiles involves multiple strategies at both the vector genome and capsid levels. Here is a breakdown of these strategies: Vector Genome Level: Modifying Vector Genome Sequences: Scientists modify AAV vector genomes by adding, mutating, or deleting specific sequences. For example, self-complementary AAV (scAAV) vectors are designed by deleting key signals from the second inverted terminal repeat (ITR), allowing for more efficient genome replication. Codon Optimization: Optimizing the codon usage of the transgene can enhance its expression efficiency. Promoter and PolyA Sequence Selection: Careful selection and manipulation of promoter and polyadenylation (polyA) sequences can influence transgene expression and tissue specificity. Capsid Engineering: Capsid engineering strategies can be categorized into four main categories: Directed Evolution: This approach involves creating capsid mutant libraries using error-prone PCR or introducing pepti
Read more